nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—BCHE—Cisplatin—testicular cancer	0.301	0.391	CbGbCtD
Neostigmine—ABCB1—Dactinomycin—testicular cancer	0.133	0.173	CbGbCtD
Neostigmine—ABCB1—Vinblastine—testicular cancer	0.0833	0.108	CbGbCtD
Neostigmine—ABCB1—Cisplatin—testicular cancer	0.0763	0.0993	CbGbCtD
Neostigmine—ABCB1—Etoposide—testicular cancer	0.075	0.0975	CbGbCtD
Neostigmine—ABCB1—Doxorubicin—testicular cancer	0.0512	0.0665	CbGbCtD
Neostigmine—ABCB1—Methotrexate—testicular cancer	0.0496	0.0644	CbGbCtD
Neostigmine—Mental disorder—Ifosfamide—testicular cancer	0.00107	0.00462	CcSEcCtD
Neostigmine—Dysarthria—Doxorubicin—testicular cancer	0.00105	0.00455	CcSEcCtD
Neostigmine—Coma—Methotrexate—testicular cancer	0.00105	0.00454	CcSEcCtD
Neostigmine—Salivary hypersecretion—Epirubicin—testicular cancer	0.00104	0.00452	CcSEcCtD
Neostigmine—Urticaria—Chlorambucil—testicular cancer	0.00104	0.0045	CcSEcCtD
Neostigmine—Urinary tract disorder—Cisplatin—testicular cancer	0.00104	0.00449	CcSEcCtD
Neostigmine—Abdominal pain—Chlorambucil—testicular cancer	0.00103	0.00448	CcSEcCtD
Neostigmine—Connective tissue disorder—Cisplatin—testicular cancer	0.00103	0.00447	CcSEcCtD
Neostigmine—Urethral disorder—Cisplatin—testicular cancer	0.00103	0.00446	CcSEcCtD
Neostigmine—Atrioventricular block—Doxorubicin—testicular cancer	0.00102	0.00444	CcSEcCtD
Neostigmine—Anaphylactic shock—Bleomycin—testicular cancer	0.00101	0.00439	CcSEcCtD
Neostigmine—Coma—Epirubicin—testicular cancer	0.000982	0.00425	CcSEcCtD
Neostigmine—Gastrointestinal pain—Vinblastine—testicular cancer	0.000981	0.00425	CcSEcCtD
Neostigmine—Flushing—Cisplatin—testicular cancer	0.000975	0.00422	CcSEcCtD
Neostigmine—Agitation—Ifosfamide—testicular cancer	0.000975	0.00422	CcSEcCtD
Neostigmine—Salivary hypersecretion—Doxorubicin—testicular cancer	0.000965	0.00418	CcSEcCtD
Neostigmine—Hypersensitivity—Chlorambucil—testicular cancer	0.000964	0.00418	CcSEcCtD
Neostigmine—Urinary tract disorder—Etoposide—testicular cancer	0.00095	0.00412	CcSEcCtD
Neostigmine—Abdominal pain—Vinblastine—testicular cancer	0.000948	0.00411	CcSEcCtD
Neostigmine—Mediastinal disorder—Cisplatin—testicular cancer	0.000947	0.0041	CcSEcCtD
Neostigmine—Hypotension—Bleomycin—testicular cancer	0.000946	0.0041	CcSEcCtD
Neostigmine—Urethral disorder—Etoposide—testicular cancer	0.000943	0.00409	CcSEcCtD
Neostigmine—Asthenia—Chlorambucil—testicular cancer	0.000939	0.00407	CcSEcCtD
Neostigmine—Arrhythmia—Cisplatin—testicular cancer	0.000938	0.00406	CcSEcCtD
Neostigmine—Pruritus—Chlorambucil—testicular cancer	0.000926	0.00401	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000923	0.004	CcSEcCtD
Neostigmine—Convulsion—Ifosfamide—testicular cancer	0.000919	0.00398	CcSEcCtD
Neostigmine—Coma—Doxorubicin—testicular cancer	0.000908	0.00393	CcSEcCtD
Neostigmine—Dyspnoea—Bleomycin—testicular cancer	0.000903	0.00391	CcSEcCtD
Neostigmine—Arthralgia—Ifosfamide—testicular cancer	0.000903	0.00391	CcSEcCtD
Neostigmine—Flatulence—Cisplatin—testicular cancer	0.000901	0.0039	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000897	0.00388	CcSEcCtD
Neostigmine—Diarrhoea—Chlorambucil—testicular cancer	0.000895	0.00388	CcSEcCtD
Neostigmine—Flushing—Etoposide—testicular cancer	0.000893	0.00387	CcSEcCtD
Neostigmine—Hypersensitivity—Vinblastine—testicular cancer	0.000884	0.00383	CcSEcCtD
Neostigmine—Muscle spasms—Cisplatin—testicular cancer	0.000879	0.00381	CcSEcCtD
Neostigmine—Mediastinal disorder—Etoposide—testicular cancer	0.000867	0.00376	CcSEcCtD
Neostigmine—Anaphylactic shock—Ifosfamide—testicular cancer	0.000866	0.00375	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000861	0.00373	CcSEcCtD
Neostigmine—Asthenia—Vinblastine—testicular cancer	0.00086	0.00373	CcSEcCtD
Neostigmine—Nervous system disorder—Ifosfamide—testicular cancer	0.000849	0.00368	CcSEcCtD
Neostigmine—Skin disorder—Ifosfamide—testicular cancer	0.000841	0.00364	CcSEcCtD
Neostigmine—Hyperhidrosis—Ifosfamide—testicular cancer	0.000837	0.00362	CcSEcCtD
Neostigmine—Osteoarthritis—Methotrexate—testicular cancer	0.000833	0.00361	CcSEcCtD
Neostigmine—Vomiting—Chlorambucil—testicular cancer	0.000832	0.0036	CcSEcCtD
Neostigmine—Diarrhoea—Vinblastine—testicular cancer	0.000821	0.00355	CcSEcCtD
Neostigmine—Hypotension—Ifosfamide—testicular cancer	0.000809	0.0035	CcSEcCtD
Neostigmine—Muscle spasms—Etoposide—testicular cancer	0.000805	0.00349	CcSEcCtD
Neostigmine—Urticaria—Bleomycin—testicular cancer	0.000805	0.00348	CcSEcCtD
Neostigmine—Dizziness—Vinblastine—testicular cancer	0.000793	0.00343	CcSEcCtD
Neostigmine—Convulsion—Cisplatin—testicular cancer	0.000792	0.00343	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000789	0.00342	CcSEcCtD
Neostigmine—Osteoarthritis—Epirubicin—testicular cancer	0.00078	0.00338	CcSEcCtD
Neostigmine—Nausea—Chlorambucil—testicular cancer	0.000777	0.00337	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000773	0.00335	CcSEcCtD
Neostigmine—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000772	0.00335	CcSEcCtD
Neostigmine—Dyspnoea—Ifosfamide—testicular cancer	0.000772	0.00334	CcSEcCtD
Neostigmine—Somnolence—Ifosfamide—testicular cancer	0.00077	0.00333	CcSEcCtD
Neostigmine—Vomiting—Vinblastine—testicular cancer	0.000763	0.0033	CcSEcCtD
Neostigmine—Headache—Vinblastine—testicular cancer	0.000751	0.00325	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000747	0.00324	CcSEcCtD
Neostigmine—Abdominal pain—Dactinomycin—testicular cancer	0.000747	0.00323	CcSEcCtD
Neostigmine—Anaphylactic shock—Cisplatin—testicular cancer	0.000746	0.00323	CcSEcCtD
Neostigmine—Hypersensitivity—Bleomycin—testicular cancer	0.000746	0.00323	CcSEcCtD
Neostigmine—Cardiac arrest—Epirubicin—testicular cancer	0.000741	0.00321	CcSEcCtD
Neostigmine—Loss of consciousness—Etoposide—testicular cancer	0.000736	0.00319	CcSEcCtD
Neostigmine—Nervous system disorder—Cisplatin—testicular cancer	0.000732	0.00317	CcSEcCtD
Neostigmine—Tachycardia—Cisplatin—testicular cancer	0.000728	0.00315	CcSEcCtD
Neostigmine—Asthenia—Bleomycin—testicular cancer	0.000727	0.00315	CcSEcCtD
Neostigmine—Convulsion—Etoposide—testicular cancer	0.000726	0.00314	CcSEcCtD
Neostigmine—Skin disorder—Cisplatin—testicular cancer	0.000725	0.00314	CcSEcCtD
Neostigmine—Osteoarthritis—Doxorubicin—testicular cancer	0.000721	0.00312	CcSEcCtD
Neostigmine—Hyperhidrosis—Cisplatin—testicular cancer	0.000721	0.00312	CcSEcCtD
Neostigmine—Pruritus—Bleomycin—testicular cancer	0.000717	0.0031	CcSEcCtD
Neostigmine—Nausea—Vinblastine—testicular cancer	0.000712	0.00309	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000708	0.00307	CcSEcCtD
Neostigmine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000708	0.00307	CcSEcCtD
Neostigmine—Hypotension—Cisplatin—testicular cancer	0.000697	0.00302	CcSEcCtD
Neostigmine—Hypersensitivity—Dactinomycin—testicular cancer	0.000696	0.00301	CcSEcCtD
Neostigmine—Urticaria—Ifosfamide—testicular cancer	0.000688	0.00298	CcSEcCtD
Neostigmine—Cardiac arrest—Doxorubicin—testicular cancer	0.000686	0.00297	CcSEcCtD
Neostigmine—Abdominal pain—Ifosfamide—testicular cancer	0.000684	0.00296	CcSEcCtD
Neostigmine—Anaphylactic shock—Etoposide—testicular cancer	0.000684	0.00296	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00068	0.00294	CcSEcCtD
Neostigmine—Asthenia—Dactinomycin—testicular cancer	0.000678	0.00294	CcSEcCtD
Neostigmine—Tachycardia—Etoposide—testicular cancer	0.000667	0.00289	CcSEcCtD
Neostigmine—Dyspnoea—Cisplatin—testicular cancer	0.000665	0.00288	CcSEcCtD
Neostigmine—Skin disorder—Etoposide—testicular cancer	0.000664	0.00288	CcSEcCtD
Neostigmine—Hyperhidrosis—Etoposide—testicular cancer	0.000661	0.00286	CcSEcCtD
Neostigmine—Diarrhoea—Dactinomycin—testicular cancer	0.000646	0.0028	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000644	0.00279	CcSEcCtD
Neostigmine—Vomiting—Bleomycin—testicular cancer	0.000644	0.00279	CcSEcCtD
Neostigmine—Drowsiness—Methotrexate—testicular cancer	0.000642	0.00278	CcSEcCtD
Neostigmine—Hypotension—Etoposide—testicular cancer	0.000639	0.00277	CcSEcCtD
Neostigmine—Rash—Bleomycin—testicular cancer	0.000639	0.00277	CcSEcCtD
Neostigmine—Dermatitis—Bleomycin—testicular cancer	0.000638	0.00276	CcSEcCtD
Neostigmine—Hypersensitivity—Ifosfamide—testicular cancer	0.000638	0.00276	CcSEcCtD
Neostigmine—Pollakiuria—Epirubicin—testicular cancer	0.000623	0.0027	CcSEcCtD
Neostigmine—Asthenia—Ifosfamide—testicular cancer	0.000621	0.00269	CcSEcCtD
Neostigmine—Pruritus—Ifosfamide—testicular cancer	0.000612	0.00265	CcSEcCtD
Neostigmine—Dyspnoea—Etoposide—testicular cancer	0.00061	0.00264	CcSEcCtD
Neostigmine—Somnolence—Etoposide—testicular cancer	0.000608	0.00263	CcSEcCtD
Neostigmine—Nausea—Bleomycin—testicular cancer	0.000602	0.00261	CcSEcCtD
Neostigmine—Drowsiness—Epirubicin—testicular cancer	0.000601	0.0026	CcSEcCtD
Neostigmine—Vomiting—Dactinomycin—testicular cancer	0.000601	0.0026	CcSEcCtD
Neostigmine—Rash—Dactinomycin—testicular cancer	0.000596	0.00258	CcSEcCtD
Neostigmine—Diarrhoea—Ifosfamide—testicular cancer	0.000592	0.00257	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00059	0.00256	CcSEcCtD
Neostigmine—Pollakiuria—Doxorubicin—testicular cancer	0.000576	0.00249	CcSEcCtD
Neostigmine—Dizziness—Ifosfamide—testicular cancer	0.000572	0.00248	CcSEcCtD
Neostigmine—Urinary tract disorder—Methotrexate—testicular cancer	0.000569	0.00247	CcSEcCtD
Neostigmine—Urethral disorder—Methotrexate—testicular cancer	0.000565	0.00245	CcSEcCtD
Neostigmine—Nausea—Dactinomycin—testicular cancer	0.000561	0.00243	CcSEcCtD
Neostigmine—Gastrointestinal pain—Etoposide—testicular cancer	0.000559	0.00242	CcSEcCtD
Neostigmine—Drowsiness—Doxorubicin—testicular cancer	0.000556	0.00241	CcSEcCtD
Neostigmine—Vomiting—Ifosfamide—testicular cancer	0.00055	0.00238	CcSEcCtD
Neostigmine—Hypersensitivity—Cisplatin—testicular cancer	0.00055	0.00238	CcSEcCtD
Neostigmine—Bradycardia—Epirubicin—testicular cancer	0.000549	0.00238	CcSEcCtD
Neostigmine—Rash—Ifosfamide—testicular cancer	0.000546	0.00236	CcSEcCtD
Neostigmine—Dermatitis—Ifosfamide—testicular cancer	0.000545	0.00236	CcSEcCtD
Neostigmine—Urticaria—Etoposide—testicular cancer	0.000543	0.00235	CcSEcCtD
Neostigmine—Abdominal pain—Etoposide—testicular cancer	0.00054	0.00234	CcSEcCtD
Neostigmine—Asthenia—Cisplatin—testicular cancer	0.000535	0.00232	CcSEcCtD
Neostigmine—Urinary tract disorder—Epirubicin—testicular cancer	0.000533	0.00231	CcSEcCtD
Neostigmine—Connective tissue disorder—Epirubicin—testicular cancer	0.00053	0.0023	CcSEcCtD
Neostigmine—Urethral disorder—Epirubicin—testicular cancer	0.000529	0.00229	CcSEcCtD
Neostigmine—Mediastinal disorder—Methotrexate—testicular cancer	0.000519	0.00225	CcSEcCtD
Neostigmine—Nausea—Ifosfamide—testicular cancer	0.000514	0.00223	CcSEcCtD
Neostigmine—Diarrhoea—Cisplatin—testicular cancer	0.000511	0.00221	CcSEcCtD
Neostigmine—Bradycardia—Doxorubicin—testicular cancer	0.000508	0.0022	CcSEcCtD
Neostigmine—Mental disorder—Methotrexate—testicular cancer	0.000505	0.00219	CcSEcCtD
Neostigmine—Hypersensitivity—Etoposide—testicular cancer	0.000504	0.00218	CcSEcCtD
Neostigmine—Flushing—Epirubicin—testicular cancer	0.000501	0.00217	CcSEcCtD
Neostigmine—Urinary tract disorder—Doxorubicin—testicular cancer	0.000493	0.00213	CcSEcCtD
Neostigmine—Asthenia—Etoposide—testicular cancer	0.000491	0.00212	CcSEcCtD
Neostigmine—Connective tissue disorder—Doxorubicin—testicular cancer	0.00049	0.00212	CcSEcCtD
Neostigmine—Urethral disorder—Doxorubicin—testicular cancer	0.000489	0.00212	CcSEcCtD
Neostigmine—Mediastinal disorder—Epirubicin—testicular cancer	0.000486	0.00211	CcSEcCtD
Neostigmine—Pruritus—Etoposide—testicular cancer	0.000484	0.00209	CcSEcCtD
Neostigmine—Arrhythmia—Epirubicin—testicular cancer	0.000482	0.00209	CcSEcCtD
Neostigmine—Vomiting—Cisplatin—testicular cancer	0.000474	0.00206	CcSEcCtD
Neostigmine—Mental disorder—Epirubicin—testicular cancer	0.000473	0.00205	CcSEcCtD
Neostigmine—Rash—Cisplatin—testicular cancer	0.000471	0.00204	CcSEcCtD
Neostigmine—Dermatitis—Cisplatin—testicular cancer	0.00047	0.00204	CcSEcCtD
Neostigmine—Diarrhoea—Etoposide—testicular cancer	0.000468	0.00203	CcSEcCtD
Neostigmine—Flushing—Doxorubicin—testicular cancer	0.000463	0.00201	CcSEcCtD
Neostigmine—Flatulence—Epirubicin—testicular cancer	0.000463	0.002	CcSEcCtD
Neostigmine—Dizziness—Etoposide—testicular cancer	0.000452	0.00196	CcSEcCtD
Neostigmine—Muscle spasms—Epirubicin—testicular cancer	0.000451	0.00196	CcSEcCtD
Neostigmine—Mediastinal disorder—Doxorubicin—testicular cancer	0.00045	0.00195	CcSEcCtD
Neostigmine—Arrhythmia—Doxorubicin—testicular cancer	0.000446	0.00193	CcSEcCtD
Neostigmine—Nausea—Cisplatin—testicular cancer	0.000443	0.00192	CcSEcCtD
Neostigmine—Mental disorder—Doxorubicin—testicular cancer	0.000437	0.00189	CcSEcCtD
Neostigmine—Convulsion—Methotrexate—testicular cancer	0.000435	0.00188	CcSEcCtD
Neostigmine—Vomiting—Etoposide—testicular cancer	0.000435	0.00188	CcSEcCtD
Neostigmine—Agitation—Epirubicin—testicular cancer	0.000432	0.00187	CcSEcCtD
Neostigmine—Rash—Etoposide—testicular cancer	0.000431	0.00187	CcSEcCtD
Neostigmine—Dermatitis—Etoposide—testicular cancer	0.000431	0.00187	CcSEcCtD
Neostigmine—Headache—Etoposide—testicular cancer	0.000428	0.00185	CcSEcCtD
Neostigmine—Flatulence—Doxorubicin—testicular cancer	0.000428	0.00185	CcSEcCtD
Neostigmine—Arthralgia—Methotrexate—testicular cancer	0.000427	0.00185	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000424	0.00184	CcSEcCtD
Neostigmine—Syncope—Epirubicin—testicular cancer	0.000421	0.00182	CcSEcCtD
Neostigmine—Muscle spasms—Doxorubicin—testicular cancer	0.000418	0.00181	CcSEcCtD
Neostigmine—Loss of consciousness—Epirubicin—testicular cancer	0.000413	0.00179	CcSEcCtD
Neostigmine—Anaphylactic shock—Methotrexate—testicular cancer	0.00041	0.00177	CcSEcCtD
Neostigmine—Convulsion—Epirubicin—testicular cancer	0.000407	0.00176	CcSEcCtD
Neostigmine—Nausea—Etoposide—testicular cancer	0.000406	0.00176	CcSEcCtD
Neostigmine—Nervous system disorder—Methotrexate—testicular cancer	0.000402	0.00174	CcSEcCtD
Neostigmine—Arthralgia—Epirubicin—testicular cancer	0.0004	0.00173	CcSEcCtD
Neostigmine—Agitation—Doxorubicin—testicular cancer	0.000399	0.00173	CcSEcCtD
Neostigmine—Skin disorder—Methotrexate—testicular cancer	0.000398	0.00172	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000397	0.00172	CcSEcCtD
Neostigmine—Hyperhidrosis—Methotrexate—testicular cancer	0.000396	0.00171	CcSEcCtD
Neostigmine—Dry mouth—Epirubicin—testicular cancer	0.000391	0.00169	CcSEcCtD
Neostigmine—Syncope—Doxorubicin—testicular cancer	0.00039	0.00169	CcSEcCtD
Neostigmine—Anaphylactic shock—Epirubicin—testicular cancer	0.000383	0.00166	CcSEcCtD
Neostigmine—Hypotension—Methotrexate—testicular cancer	0.000383	0.00166	CcSEcCtD
Neostigmine—Loss of consciousness—Doxorubicin—testicular cancer	0.000382	0.00165	CcSEcCtD
Neostigmine—Shock—Epirubicin—testicular cancer	0.000377	0.00163	CcSEcCtD
Neostigmine—Convulsion—Doxorubicin—testicular cancer	0.000376	0.00163	CcSEcCtD
Neostigmine—Nervous system disorder—Epirubicin—testicular cancer	0.000376	0.00163	CcSEcCtD
Neostigmine—Tachycardia—Epirubicin—testicular cancer	0.000374	0.00162	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000373	0.00162	CcSEcCtD
Neostigmine—Skin disorder—Epirubicin—testicular cancer	0.000372	0.00161	CcSEcCtD
Neostigmine—Hyperhidrosis—Epirubicin—testicular cancer	0.00037	0.0016	CcSEcCtD
Neostigmine—Insomnia—Methotrexate—testicular cancer	0.00037	0.0016	CcSEcCtD
Neostigmine—Arthralgia—Doxorubicin—testicular cancer	0.00037	0.0016	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000367	0.00159	CcSEcCtD
Neostigmine—Dyspnoea—Methotrexate—testicular cancer	0.000365	0.00158	CcSEcCtD
Neostigmine—Somnolence—Methotrexate—testicular cancer	0.000364	0.00158	CcSEcCtD
Neostigmine—Dry mouth—Doxorubicin—testicular cancer	0.000362	0.00157	CcSEcCtD
Neostigmine—Hypotension—Epirubicin—testicular cancer	0.000358	0.00155	CcSEcCtD
Neostigmine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000355	0.00154	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000354	0.00153	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000349	0.00151	CcSEcCtD
Neostigmine—Shock—Doxorubicin—testicular cancer	0.000349	0.00151	CcSEcCtD
Neostigmine—Nervous system disorder—Doxorubicin—testicular cancer	0.000348	0.00151	CcSEcCtD
Neostigmine—Insomnia—Epirubicin—testicular cancer	0.000347	0.0015	CcSEcCtD
Neostigmine—Tachycardia—Doxorubicin—testicular cancer	0.000346	0.0015	CcSEcCtD
Neostigmine—Skin disorder—Doxorubicin—testicular cancer	0.000344	0.00149	CcSEcCtD
Neostigmine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000343	0.00148	CcSEcCtD
Neostigmine—Dyspnoea—Epirubicin—testicular cancer	0.000342	0.00148	CcSEcCtD
Neostigmine—Somnolence—Epirubicin—testicular cancer	0.000341	0.00148	CcSEcCtD
Neostigmine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000335	0.00145	CcSEcCtD
Neostigmine—Hypotension—Doxorubicin—testicular cancer	0.000331	0.00144	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000331	0.00143	CcSEcCtD
Neostigmine—Urticaria—Methotrexate—testicular cancer	0.000325	0.00141	CcSEcCtD
Neostigmine—Abdominal pain—Methotrexate—testicular cancer	0.000324	0.0014	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000323	0.0014	CcSEcCtD
Neostigmine—Insomnia—Doxorubicin—testicular cancer	0.000321	0.00139	CcSEcCtD
Neostigmine—Dyspnoea—Doxorubicin—testicular cancer	0.000316	0.00137	CcSEcCtD
Neostigmine—Somnolence—Doxorubicin—testicular cancer	0.000315	0.00137	CcSEcCtD
Neostigmine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000313	0.00136	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000306	0.00133	CcSEcCtD
Neostigmine—Urticaria—Epirubicin—testicular cancer	0.000304	0.00132	CcSEcCtD
Neostigmine—Abdominal pain—Epirubicin—testicular cancer	0.000303	0.00131	CcSEcCtD
Neostigmine—Hypersensitivity—Methotrexate—testicular cancer	0.000302	0.00131	CcSEcCtD
Neostigmine—Asthenia—Methotrexate—testicular cancer	0.000294	0.00127	CcSEcCtD
Neostigmine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00029	0.00126	CcSEcCtD
Neostigmine—Pruritus—Methotrexate—testicular cancer	0.00029	0.00125	CcSEcCtD
Neostigmine—Hypersensitivity—Epirubicin—testicular cancer	0.000282	0.00122	CcSEcCtD
Neostigmine—Urticaria—Doxorubicin—testicular cancer	0.000282	0.00122	CcSEcCtD
Neostigmine—Abdominal pain—Doxorubicin—testicular cancer	0.00028	0.00121	CcSEcCtD
Neostigmine—Diarrhoea—Methotrexate—testicular cancer	0.00028	0.00121	CcSEcCtD
Neostigmine—Asthenia—Epirubicin—testicular cancer	0.000275	0.00119	CcSEcCtD
Neostigmine—Pruritus—Epirubicin—testicular cancer	0.000271	0.00117	CcSEcCtD
Neostigmine—Dizziness—Methotrexate—testicular cancer	0.000271	0.00117	CcSEcCtD
Neostigmine—Diarrhoea—Epirubicin—testicular cancer	0.000262	0.00114	CcSEcCtD
Neostigmine—Hypersensitivity—Doxorubicin—testicular cancer	0.000261	0.00113	CcSEcCtD
Neostigmine—Vomiting—Methotrexate—testicular cancer	0.00026	0.00113	CcSEcCtD
Neostigmine—Rash—Methotrexate—testicular cancer	0.000258	0.00112	CcSEcCtD
Neostigmine—Dermatitis—Methotrexate—testicular cancer	0.000258	0.00112	CcSEcCtD
Neostigmine—Headache—Methotrexate—testicular cancer	0.000257	0.00111	CcSEcCtD
Neostigmine—Asthenia—Doxorubicin—testicular cancer	0.000254	0.0011	CcSEcCtD
Neostigmine—Dizziness—Epirubicin—testicular cancer	0.000253	0.0011	CcSEcCtD
Neostigmine—Pruritus—Doxorubicin—testicular cancer	0.000251	0.00109	CcSEcCtD
Neostigmine—Vomiting—Epirubicin—testicular cancer	0.000244	0.00106	CcSEcCtD
Neostigmine—Nausea—Methotrexate—testicular cancer	0.000243	0.00105	CcSEcCtD
Neostigmine—Diarrhoea—Doxorubicin—testicular cancer	0.000243	0.00105	CcSEcCtD
Neostigmine—Rash—Epirubicin—testicular cancer	0.000242	0.00105	CcSEcCtD
Neostigmine—Dermatitis—Epirubicin—testicular cancer	0.000241	0.00105	CcSEcCtD
Neostigmine—Headache—Epirubicin—testicular cancer	0.00024	0.00104	CcSEcCtD
Neostigmine—Dizziness—Doxorubicin—testicular cancer	0.000234	0.00102	CcSEcCtD
Neostigmine—Nausea—Epirubicin—testicular cancer	0.000228	0.000986	CcSEcCtD
Neostigmine—Vomiting—Doxorubicin—testicular cancer	0.000225	0.000976	CcSEcCtD
Neostigmine—Rash—Doxorubicin—testicular cancer	0.000224	0.000968	CcSEcCtD
Neostigmine—Dermatitis—Doxorubicin—testicular cancer	0.000223	0.000967	CcSEcCtD
Neostigmine—Headache—Doxorubicin—testicular cancer	0.000222	0.000962	CcSEcCtD
Neostigmine—Nausea—Doxorubicin—testicular cancer	0.000211	0.000912	CcSEcCtD
